Apnimed, Inc.(APMD)

Biotechnology · Cambridge, MA

$21.75+0.24 (+1.12%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T13:25:26.193Z.

Stored calculation inputs

Calculation as of: 2026-10-06T13:25:26.193Z.

Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 866,154,230
Total debt: N/A
Cash: N/A
TTM operating EBITDA: N/A

FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

APMD EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

APMD Competitors' EV/EBITDA Ratio

APMD

Apnimed, Inc.

Current

Market Cap

$866.15M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GLUE

Monte Rosa Therapeutics, Inc.

vs APMD

Market Cap

$867.60M

EV/EBITDA Ratio

N/A

TTM Avg

45.75x

3Y Avg

45.75x

5Y Avg

45.75x

JBIO

Jade Biosciences, Inc.

vs APMD

Market Cap

$856.30M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BBNX

Beta Bionics, Inc.

vs APMD

Market Cap

$852.55M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALMS

Alumis Inc.

vs APMD

Market Cap

$844.28M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ARDX

Ardelyx, Inc.

vs APMD

Market Cap

$837.43M

EV/EBITDA Ratio

N/A

TTM Avg

7.99x

3Y Avg

7.99x

5Y Avg

7.99x

CRVS

Corvus Pharmaceuticals, Inc.

vs APMD

Market Cap

$903.13M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GYRE

Gyre Therapeutics, Inc.

vs APMD

Market Cap

$819.44M

EV/EBITDA Ratio

N/A

TTM Avg

76.03x

3Y Avg

57.10x

5Y Avg

57.10x

BVS

Bioventus Inc.

vs APMD

Market Cap

$915.95M

EV/EBITDA Ratio

10.74x

TTM Avg

9.34x

3Y Avg

18.56x

5Y Avg

25.76x

INMD

InMode Ltd.

vs APMD

Market Cap

$812.20M

EV/EBITDA Ratio

6.02x

TTM Avg

7.11x

3Y Avg

8.26x

5Y Avg

13.78x

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Apnimed, Inc. (APMD)	$866.15M	N/A	N/A	N/A	N/A
Monte Rosa Therapeutics, Inc. (GLUE)vs ›	$867.60M	N/A	45.75x	45.75x	45.75x
Jade Biosciences, Inc. (JBIO)vs ›	$856.30M	N/A	N/A	N/A	N/A
Beta Bionics, Inc. (BBNX)vs ›	$852.55M	N/A	N/A	N/A	N/A
Alumis Inc. (ALMS)vs ›	$844.28M	N/A	N/A	N/A	N/A
Ardelyx, Inc. (ARDX)vs ›	$837.43M	N/A	7.99x	7.99x	7.99x
Corvus Pharmaceuticals, Inc. (CRVS)vs ›	$903.13M	N/A	N/A	N/A	N/A
Gyre Therapeutics, Inc. (GYRE)vs ›	$819.44M	N/A	76.03x	57.10x	57.10x
Bioventus Inc. (BVS)vs ›	$915.95M	10.74x	9.34x	18.56x	25.76x
InMode Ltd. (INMD)vs ›	$812.20M	6.02x	7.11x	8.26x	13.78x

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics